PARP inhibitors for breast cancer take centre stage at ASCO
This article was originally published in Scrip
Executive Summary
A new class of anticancer drug, the PARP inhibitors, took centre stage at the ASCO meeting in Orlando after Phase II studies revealed their promise in specific subtypes of breast and ovarian cancer.